

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Guselkumab Subcutaneous 200 mg (Tremfya Subcutaneous 200 mg)

Notes:

- Quantity Limits: Yes
- ^ Adequate trial is defined as the following:
 - Biologics – 12 weeks
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria and criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:

Non-formulary **guselkumab subcutaneous 200 mg (Tremfya subcutaneous 200 mg)** will be covered on the prescription drug benefit for when the following criteria are met:

1. Prescriber is a gastroenterologist and patient has a diagnosis of moderate to severe ulcerative colitis
 - Patient has failed an adequate trial[^], has an intolerance^{*}, or has a contraindication to the following:
 - Infliximab product
 - Ustekinumab product (criteria based)
 - Patient has received, or is scheduled to receive, 3 loading doses of guselkumab IV

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **guselkumab subcutaneous 200 mg (Tremfya subcutaneous 200 mg)** will be covered on the prescription drug benefit for when the following criteria are met:

1. Prescriber is a gastroenterologist and patient has a diagnosis of moderate to severe ulcerative colitis
 - Patient is currently stable on guselkumab